retatrutide mechanism retatrutide clinical trials 2024 2025 Dosing Guide: 1-12 mg Weekly Triple Agonist (2026) ADA 2026: Retatrutide Revolution

99, 2024, OC12.5, Pelusi, Carla, and Renato Pasquali

Primary endpoint Percentage weight loss at M6 was statistically significantly higher in the GLP-1-RA group than in the UCWM group (12.0% [3.3] vs

Always try to find the full name of any 'pep' you encounter

Stress, hormonal cycles (particularly in women), and underlying metabolic conditions like insulin resistance can delay noticeable progress by one to two weeks

These developments might increase access to care and give innovators a stronger edge over rivals

Those results, showing 28.7% weight loss at the 12mg dose, have generated enormous excitement and set a high bar for what TRIUMPH-1 might confirm in a broader obesity population